Reversal of HIV latency in vivo

HIV体内潜伏期的逆转

基本信息

项目摘要

We propose to perform three small, focused clinical trials aimed at reversing HIV latency in long-term antiretroviral-treated adults. While our proposed studies seek to translate findings from the laboratory into the clinic, they are also designed to enable our laboratory-based scientists to further investigate the mechanisms that contribute to latency. We believe that this "reverse translation" is critical to advancing our knowledge about the biology of HIV persistence during therapy. In Specific Aim 1, we will perform a two-center, single arm, limited duration (two weeks) clinical study investigating the ability of disulfiram (an FDA-approved drug to treat alcoholism) to reverse HIV latency. This study is based on recent data from Dr. Siliciano and colleagues: using a primary cell assay for HIV latency developed by his laboratory to identify compounds that activate latent HIV, his group identified this drug as among the most promising agents. This study has received approval from the FDA and the Johns Hopkins IRB, and tentative approval from the UCSF IRB. In Specific Aim 2, we will perform a single-center, randomized, controlled study investigating the ability of maraviroc (a CCR5 inhibitor) to reverse latency. This study is based on emerging data from our group suggesting that this drug may directly affect latent HIV genomes independent of its effect on viral replication. We will work closely with Dr. Sharon Lewin (Project 5) to explore the potential mechanism for this effect. Our group has performed a similar study recently and expects to have no regulatory or logistical barriers to completing the study within one to two years. In Specific Aim 3, we will perform a limited center, dose-escalating phase I study of an anti-PD-1 antibody. This study is based on preliminary data outlined in Project 2 and 3, and will be performed within the ACTG using drug to be provided by Dr. Hazuda and her colleagues. This study has received ACTG approval for full protocol development. U19 funds will be used to support the intensive virology.
我们建议进行三项旨在长期逆转HIV潜伏期的小型、重点临床试验

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN Grant DEEKS其他文献

STEVEN Grant DEEKS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN Grant DEEKS', 18)}}的其他基金

Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    10626936
  • 财政年份:
    2021
  • 资助金额:
    $ 39.51万
  • 项目类别:
Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    10313930
  • 财政年份:
    2021
  • 资助金额:
    $ 39.51万
  • 项目类别:
Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    10469472
  • 财政年份:
    2021
  • 资助金额:
    $ 39.51万
  • 项目类别:
Therapeutic vaccination and PD-1 blockade in treated HIV disease
治疗性疫苗接种和 PD-1 阻断治疗 HIV 疾病
  • 批准号:
    9322064
  • 财政年份:
    2017
  • 资助金额:
    $ 39.51万
  • 项目类别:
Therapeutic vaccination and PD-1 blockade in treated HIV disease
治疗性疫苗接种和 PD-1 阻断治疗 HIV 疾病
  • 批准号:
    9902324
  • 财政年份:
    2017
  • 资助金额:
    $ 39.51万
  • 项目类别:
Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    9978687
  • 财政年份:
    2016
  • 资助金额:
    $ 39.51万
  • 项目类别:
Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    9315694
  • 财政年份:
    2016
  • 资助金额:
    $ 39.51万
  • 项目类别:
Delaney AIDS Research Enterprise to Cure HIV
德莱尼艾滋病研究企业治愈艾滋病毒
  • 批准号:
    9190154
  • 财政年份:
    2016
  • 资助金额:
    $ 39.51万
  • 项目类别:
DARE: Delaney AIDS Research Enterprise to find a cure.
敢于:德莱尼艾滋病研究企业寻找治疗方法。
  • 批准号:
    8703593
  • 财政年份:
    2011
  • 资助金额:
    $ 39.51万
  • 项目类别:
DARE: Delaney AIDS Research Enterprise to find a cure.
敢于:德莱尼艾滋病研究企业寻找治疗方法。
  • 批准号:
    8299019
  • 财政年份:
    2011
  • 资助金额:
    $ 39.51万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 39.51万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 39.51万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 39.51万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 39.51万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 39.51万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了